What changed
$SYK — BUY 📊 | 6 MONTHS THESIS
🎯 Q1 2026 | Rev $6.0B | EPS $2.60 vs $2.98 🔴 | Margin 25.7%
💡 The market is overreacting to a single-quarter miss, ignoring the maintained full-year guidance. Consensus may extrapolate the miss, but the underlying business remains strong with 8–9.5% organic growth. Forward P/E of 20x is below SYK’s historical premium to peers.
📉 Reward/risk: 1.93:1
🏢 Business Quality: 8/10 - Leading medtech platform with wide moats in orthopedics, surgical technologies, and neurotechnology; recurring revenue, high barriers, and mid-to-high single-digit organic growth.
📊 Valuation: cheap — forward P/E ~20x (midpoint $15) vs. historical forward P/E typically 25x+; FCF yield likely >4%.
🔮 Catalyst: Stabilization of analyst EPS estimates and market digestion of maintained guidance
💰 Entry: $301, stop $286, target $330
📊 Our read: BUY. Full analysis →
https://stockduty.xyz/s/SYK0618